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IntroductIon
CD49d, the α chain of the CD49d/CD29 integrin het-
erodimer very late antigen 4 (VLA-4), expressed in ∼40% 
of chronic lymphocytic leukemia (CLL) cases, has emerged 
as one of the most relevant biological predictors of overall 
survival (OS) and progression-free survival (PFS) in CLL 
(Gattei et al., 2008; Shanafelt et al., 2008; Bulian et al., 2014). 
VLA-4 mediates both cell–cell and cell–matrix interactions 
in CLL-involved tissues by respectively binding to its ligands 
vascular cell adhesion molecule 1 (VCAM-1) and fibronectin 
(Ruoslahti, 1991; Hartmann et al., 2009).
VLA-4, usually present on the cell surface of resting 
leukocytes in an inactive conformation, can be activated 
in response to different stimuli, thus becoming competent 
for high-affinity and high-avidity interactions (Arana et al., 
2008a). In particular, in normal B lymphocytes, stimuli orig-
inating from the B cell receptor (BCR) have been described 
to activate VLA-4 via inside-out signaling, an interplay occur-
ring during the process of antigen-specific B cell differentia-
tion that takes place in secondary lymphoid organs (Liu and 
Arpin, 1997). In this context, a proper BCR stimulation may 
trigger a cascade of molecular events eventually leading to 
increased VLA-4 activity and rescue of B cells from apoptosis 
through tonic interactions with VCAM-1–expressing follicu-
lar dendritic cells (Arana et al., 2008a).
Although not yet investigated in detail, such a BCR–
VLA-4 interplay may be relevant in CLL particularly in the 
light of the central role played by the BCR pathway in this 
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disease (Burger and Chiorazzi, 2013; Wiestner, 2015), as wit-
nessed by the emerging remarkable clinical activities of several 
inhibitors that interfere with the action of key BCR-related 
intracellular enzymes (Woyach et al., 2012; Wiestner, 2014).
In particular, ibrutinib is an orally administered 
first-in-class covalent inhibitor of Bruton’s tyrosine kinase 
(BTK) that has been approved for treatment of CLL both in 
first-line and relapsed disease (Byrd et al., 2013; Farooqui et al., 
2015). Clinically, ibrutinib yields a rapid shrinkage of tumor 
masses, a parallel redistribution of CLL cells from tissue sites 
into blood with a subsequent secondary lymphocytosis (Jones 
and Byrd, 2014). This pattern of clinical response, shared by 
all inhibitors targeting the BCR pathway, is thought to occur 
through inhibition of different integrin-dependent and/
or chemokine-dependent microenvironmental interactions, 
including those mediated by VLA-4 (de Rooij et al., 2012; 
Ponader et al., 2012; Herman et al., 2015; Chen et al., 2016). 
Despite this, nothing has been reported regarding the modu-
lation of VLA-4 activation by ibrutinib and the influence of 
VLA-4 expression/activation on ibrutinib response in vivo.
In the present study, by taking advantage of three differ-
ent cohorts of in vivo ibrutinib-treated CLL and of a series of 
ibrutinib-naive primary CLL samples, we demonstrate that (1) 
the VLA-4 integrin can also be activated upon BCR trigger-
ing in ibrutinib-exposed CLL cells, (2) CLL cases expressing 
CD49d usually fail to display the canonical ibrutinib-induced 
lymphocytosis and experience a lower nodal response, and (3) 
CD49d expression is consistently associated with shorter PFS 
in the context of ibrutinib-treated CLL.
rEsuLts
Bcr stimulation induces inside-out VLA-4 
activation in cLL cells
The capability of the VLA-4 integrin to be inside-out acti-
vated by stimuli originating from the BCR (Spaargaren et 
al., 2003; Arana et al., 2008a) was tested in the context of 
CLL cells. For this purpose, we first evaluated the anti-IgM– 
induced BCR response in ibrutinib-naive cells from 30 CLL 
cases, all expressing CD49d above the established cutoff of 
30% of positive cells (Table S1; Gattei et al., 2008). BCR sig-
naling response was measured by analyzing the anti-IgM–in-
duced calcium mobilization by flow cytometry. In all cases, 
the cells responded to BCR triggering according to the 5% 
cutoff of responding cells (Fig. 1 A; Mockridge et al., 2007), 
although with variability. Similarly, CLL cells stimulated with 
anti-IgM also variably increased the phosphorylation levels 
of BTK and extracellular signal-regulated kinases (ERKs; 
Fig. 1, B and C). The virtual absence of nonresponder cases 
in this CLL cohort may be explained by the correlation of 
high CD49d expression with the presence of other negative 
prognostic factors, such an unmutated (UM) immunoglobu-
lin heavy chain variable (IGHV) mutational status and TP53 
disruption (Table S1), which have previously been shown to 
be associated with BCR responsiveness (Mockridge et al., 
2007; Apollonio et al., 2013).
We next studied in the same CLL cases the effects of 
BCR stimulation on VLA-4 activation by measuring VLA-4 
affinity by flow cytometry using a peptide ligand derived 
from the LDV sequence of the VLA-4–binding region of 
fibronectin (hereafter LDV) as VLA-4 specific ligand, along 
with the conformation sensitive anti–CD29 HUTS-21 mAb, 
to measure the VLA-4 receptor occupancy (RO) in values 
ranging from 0.0 (no RO) to 1.0 (100% RO) as previously 
described (Chigaev et al., 2009). BCR triggering significantly 
increased VLA-4 RO, when probed at fixed ligand concen-
tration (Fig.  1  D), as documented by a significant shift of 
the binding curve toward lower LDV ligand concentration, 
clearly indicating higher ligand-binding affinity (Fig.  1  E, 
left). The BCR-induced VLA-4 activation was not restricted 
to anti-IgM stimuli because anti-IgD was also able to trig-
ger the BCR signaling cascade (Fig. S1 A; Ten Hacken et al., 
2016) and efficiently elicit VLA-4 activation responses (Fig. 
S1 A). Similar results were obtained with normal B cells 
from the peripheral blood (PB) of healthy volunteers (n = 
9), where anti-IgM triggering was also able to induce a BCR 
response in terms of phospho (p)-BTK and p-AKT (Fig. S1 
B). Moreover, normal B cells, all expressing both CD29 and 
CD49d at high levels, increased VLA-4 activation upon an-
ti-IgM stimuli (Fig. S1 B).
With the aim to establish the CD49d minimum expres-
sion levels that enable activation by anti-IgM, an additional set 
of experiments were performed using CLL cells from CD49d− 
cases (i.e., expressing CD49d below the 30% clinical cutoff). In 
this context, VLA-4 RO could not be calculated for CLL cases 
with CD49d expression <10% (n = 4; not depicted) because 
these cells showed no detectable dose-dependent increase in 
the exposure of the ligand-induced epitope recognized by 
HUTS-21 (see Materials and methods for details). On the con-
trary, samples with CD49d expression between 10% and 29% 
(i.e., still formally negative) showed a dose-dependent increase 
in the exposure of the ligand-induced epitope recognized by 
HUTS-21, but no activation by anti-IgM could be observed 
(Fig. 1 F). Of note, increased VLA-4 activation upon anti-IgM 
triggering could be experimentally appreciated with CD49d 
expression levels between 30% and 60%, corresponding to in-
termediate levels of expression, thus corroborating the use of 
the 30% CD49d clinical cutoff in this setting (Fig. 1 F). The 
VLA-4 affinity change upon BCR triggering was specific to 
CLL cells because no differences in VLA-4 activation were ob-
served in the residual T cell population, whose VLA-4 activa-
tion levels remained unaffected by BCR stimulation (Fig. 1 G).
Consistently, evaluation of integrin clustering by immu-
nofluorescence analysis showed enhanced VLA-4 clustering 
after anti-IgM stimulation (Fig. 1 H), reflecting higher levels 
of avidity to the ligand (Spaargaren et al., 2003).
The VLA-4 activation correlated with the increased ca-
pacity of purified CLL cells to adhere on VCAM-1 upon BCR 
stimulation (Fig. 1 I). Adhesion data were confirmed by a dy-
namic shear flow assay on VCAM-1, where the percentage of 
arresting cells increased under anti-IgM stimulation (Fig. 1 J).
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Figure 1. triggering of the Bcr by anti-IgM induces VLA-4 activation and increases cell adhesion and VLA-4 clustering in cLL cells also upon 
ibrutinib treatment in vitro. (A) Calcium response to anti-IgM stimulation in PBMCs from 30 CLL cases. The pseudocolored dot plot on the right shows 
an example of BCR response time (in seconds) over Fluo-4 intensity in one representative CLL case. Addition of the stimulus is indicated by the arrow. 
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Bcr-mediated VLA-4 activation is retained upon 
ibrutinib treatment in vitro
The effects of ibrutinib-mediated BCR inhibition on VLA-4 
activation were then investigated in vitro using cells from the 
same CD49d+ CLL cases described above (Table S1). In keep-
ing with previous studies (Herman et al., 2014a; Woyach et al., 
2014b), 1 µM ibrutinib treatment impaired both constitutive 
and anti-IgM–stimulated BCR signaling, as witnessed by the 
significantly lower phosphorylation levels of BTK and ERK 
(Fig. S1 C) and of phospholipase C γ2 (PLCγ2) and AKT; 
these latter were evaluated in a smaller cohort of cases (n = 
10; Fig. S1 C). Moreover, consistent with a previous study 
(Woyach et al., 2014a), ibrutinib treatment decreased the an-
ti-IgM induced calcium release (Fig. S1 C). The impairment 
of the BCR-related signaling under ibrutinib was also ev-
ident when comparing the phosphorylation levels of BTK 
and the immediate downstream PLCγ2, which did not sig-
nificantly differ between the anti-IgM and the unstimulated 
conditions under ibrutinib. However, we observed a resid-
ual activity of both AKT and ERK, whose phosphorylation 
levels were found to increase upon anti-IgM triggering also 
under ibrutinib (Fig. S1 C).
Despite the overall lower BCR signaling caused by 
CLL exposure to ibrutinib, ibrutinib-treated CLL cells 
unexpectedly retained their capability to activate VLA-4 
upon anti-IgM triggering. Indeed, the VLA-4 RO values 
measured after anti-IgM stimulation increased significantly, 
reaching levels comparable with those observed in ibru-
tinib-naive cells (Fig.  1 D), and the binding curve shifted 
accordingly (Fig.  1 E, right). Moreover, despite an overall 
impairment of the anti-IgM–induced VLA-4 clustering 
upon ibrutinib treatment compared with the untreated con-
dition, BCR triggering was still able to induce VLA-4 clus-
ters in the context of ibrutinib-treated cells, suggesting that 
the integrin avidity for the ligand is only partially affected 
by BTK inhibition (Fig. 1 H).
In keeping with the retention of VLA-4 activation, 
CLL cells treated in vitro with ibrutinib were still able to 
increase their adhesion levels on VCAM-1 upon anti-IgM 
stimulation to an extent similar to that observed in ibruti-
nib-naive cells (Fig. 1 I).
Bcr-mediated VLA-4 activation is retained in 
ibrutinib-treated cLL cells in vivo
Serial samples from CLL patients treated in vivo with ibruti-
nib were collected at baseline and at days 7, 30, and 90 after 
the initiation of ibrutinib therapy.
During the course of the therapy, a progressive impair-
ment of BCR signaling was observed, as previously reported 
(Herman et al., 2014a; Woyach et al., 2014b). The constitu-
tive phosphorylation levels of BTK, ERK, PLCγ2, and AKT 
pretreatment decreased over time, reaching a significant dif-
ference at day 90 (Fig. S1 D). Moreover, anti-IgM–triggered 
BCR signaling showed a progressive decrease from pretreat-
ment to day 90 in terms of calcium release and of BTK and 
PLCγ2 phosphorylation, these last reaching phosphorylation 
levels at day 90 often comparable to their corresponding 
unstimulated conditions (Fig. S1 D). On the contrary, only 
a mild reduction of p-AKT and p-ERK was documented 
during the course of ibrutinib therapy, reaching the statistical 
significance compared with day 0 only in the case of p-AKT 
levels at day 90 (Fig. S1 D).
We then analyzed the impact of ibrutinib therapy on 
both constitutive and anti-IgM–stimulated VLA-4 activation 
as determined by measuring the RO values corresponding 
to the 10 nM LDV concentration. The levels of constitutive 
VLA-4 activation after 30 d of ibrutinib treatment were sig-
nificantly lower than pretreatment levels (n = 15; Fig. 2 A). 
Similarly, in a subgroup of CLL with samples available be-
fore treatment and at days 7, 30, and 90 on ibrutinib (n = 
7), constitutive VLA-4 activation levels observed before treat-
ment progressively decreased starting from day 7 and reached 
(B and c) MFIs of phospho (p)-BTK (B) and p-ERK (C) in unstimulated and anti-IgM stimulated cells from 24 CLL cases. The histogram plot overlays below 
the graphs show p-BTK (B) and p-ERK (C) expression in the unstimulated and anti-IgM–stimulated cells from one representative CLL case; the light gray 
histograms correspond to unstained cells. (d) VLA-4 RO in primary CLL cells from 26 cases (all cases expressing >60% CD49d), pretreated or not with 1 µM 
ibrutinib and stimulated or not with 5 µg/ml anti-IgM. The reported VLA-4 RO values were calculated as described in Materials and methods and correspond 
to the presence of 10 nM LDV. (E) VLA-4 RO plotted versus LDV concentration using the sigmoidal dose–response equation with variable slope performed 
by GraphPad Prism software in cells untreated (left) or treated with ibrutinib (right) in one representative CLL case. The arrows indicate the shift from the 
control to the anti-IgM–stimulated condition at 10 nM LDV. EC50 values for all conditions are indicated. R2 corresponds to the coefficient of determination. 
(F) VLA-4 RO in primary CLL cells expressing CD49d between 10% and 29% (n = 5) and between 30% and 60% (n = 4), pretreated or not with 1 µM ibru-
tinib and stimulated or not with 5 µg/ml anti-IgM. (G) VLA-4 RO in T lymphocytes from 15 CLL cases in unstimulated and anti-IgM–stimulated conditions. 
The line graph on the right shows the VLA-4 RO plotted versus LDV concentration obtained in T-lymphocytes from one representative CLL case. (H) VLA-4 
clusters in primary CLL cells from 3 cases treated as in (D) obtained on VCAM-1-coated slides. Quantitative clustering analysis was done in at least 50 
individual cells for each condition by means of confocal microscopy (original magnification ×60). The three dot plots correspond to three different cases 
and show the cluster number for all analyzed cells in each condition. On the right, representative confocal microscopy images of VLA-4 clusters revealed 
by anti-CD49d mAbs, are shown. Bars, 2 µm. (I) Adhesion on VCAM-1 of primary CLL cells from 15 cases treated as in D. Cell adhesion was calculated as 
relative fold change obtained on VCAM-1 over BSA. Each experiment was run in triplicate. (J) Purified CLL cells from eight cases were stimulated or not 
with anti-IgM and perfused for 1 min at 0.5 dyn/cm2 over immobilized VCAM-1. The data are expressed as the mean of frequencies of cells in direct contact 
with the substrate (tethering). Each experiment was run in triplicate. Data are presented as mean ± SEM. Individual symbols represent individual cases in 
all panels except H, which represents individual cells. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; n.s., not significant (Wilcoxon test in all panels 
except F, where a paired t test was applied).
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lower levels at days 30 and 90 (Fig. 2 B). Conversely, BCR 
triggering by anti-IgM significantly increased VLA-4 activa-
tion both in CLL cells before treatment and in CLL cells 
collected at day 30 of ibrutinib therapy (Fig. 2 A). Notably, 
BCR triggering still induced VLA-4 activation after 90 d of 
ibrutinib treatment to levels comparable with those observed 
before treatment (Fig. 2 B).
We next determined the effects of in vivo ibrutinib 
treatment on CLL cell adhesion on VCAM-1. CLL cells ob-
tained at day 30 of ibrutinib showed significantly reduced 
adhesion levels compared with pretreatment cells. Moreover, 
in line with the VLA-4 activation data, the ability of BCR 
triggering to increase VLA-4–mediated CLL cell adhesion 
observed before treatment was also maintained in CLL cells 
collected at day 30 of treatment, with no significant difference 
compared with the pretreatment condition (Fig. 2 C).
To rule out the possibility of an incomplete BTK in-
hibition in the in vivo ibrutinib-treated CLL cells used in 
our experiments, both constitutive and anti-IgM–stimulated 
BTK phosphorylation and VLA-4 activation were analyzed 
after the addition of an excess of 1  µM ibrutinib to CLL 
cells collected at day 30 of ibrutinib therapy (n = 8). In vitro, 
the addition of ibrutinib did not further inhibit the consti-
tutive and anti-IgM–stimulated phosphorylation of BTK 
(Fig. 2 D), and no difference was found in either constitutive 
or anti-IgM–stimulated VLA-4 activation levels after ibruti-
nib addition (Fig. 2 E).
Moreover, to definitely exclude the possibility that the 
observed BCR-induced VLA-4 activation characterizing CLL 
cells on ibrutinib treatment was caused by loss of BTK inhi-
bition, CLL cells were tested by next-generation sequencing 
(NGS) for the presence of BTK and PLCγ2 mutations, which 
have been reported to confer ibrutinib resistance (Woyach et 
al., 2014a). Analysis of C418S BTK mutations and R665W, 
S707Y, and L845F PLCγ2 mutations in CLL cells collected at 
day 30 of ibrutinib excluded the presence of acquired muta-
tions in all samples (n = 8; Table S1).
concomitant inhibition of BtK and PI3K 
impairs VLA-4 activation
The data reported so far suggest that BTK inhibition is not 
sufficient to block BCR-dependent VLA-4 activation. Indeed, 
BCR-induced inside-out activation of another integrin, LFA-
1, has been reported to occur through a BTK-independent 
Figure 2. Bcr-mediated VLA-4 integrin activity is not affected by ibrutinib treatment in vivo. Serial samples from 9 CLL patients were obtained 
before treatment (day 0) and at days 7, 30, and 90 on ibrutinib therapy. (A) VLA-4 RO in unstimulated and anti-IgM–stimulated CLL cells at days 0 and 30 
on ibrutinib (n = 15). (B) VLA-4 RO in unstimulated and anti-IgM–stimulated CLL cells at days 0, 7, 30, and 90 on ibrutinib (n = 7). (c) Adhesion values on 
VCAM-1 in unstimulated and anti-IgM–stimulated cells at days 0 and 30 on ibrutinib. Each adhesion experiment was run in triplicate. (d) Phospho (p)-BTK 
MFI in unstimulated and in anti-IgM–stimulated conditions obtained in CLL cells collected at day 30 of ibrutinib therapy after incubation or not in vitro 
with 1 µM ibrutinib for 1 h (n = 8). (E) VLA-4 RO in the control condition and in anti-IgM–stimulated cells in CLL cells treated as in D. Data are presented as 
mean ± SEM. Individual symbols represent individual cases. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant (Wilcoxon test).
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pathway involving phosphatidylinositide 3-kinase (PI3K; 
Arana et al., 2008a). Because residual phosphorylation of 
the downstream PI3K target AKT was observed in ibruti-
nib-treated CLL cells upon BCR stimulation (Fig. S1, C and 
D), we next investigated the effects of combined BTK and 
PI3K inhibition on BCR-induced VLA-4 activation. For this 
purpose, we treated CLL cells from 7 cases with 1 µM ibru-
tinib, 1 µM idelalisib, or a combination of both. A significant 
decrease in BTK and AKT phosphorylation levels confirmed 
the actual inhibition of the BCR pathway driven by ibrutinib 
and idelalisib, respectively (Fig. 3, A and B). Analysis of VLA-4 
activation showed that neither ibrutinib nor idelalisib, when 
used as single agents, was able to fully block the anti-IgM–
induced VLA-4 activation, whereas a concomitant inhibition 
of both BTK and PI3K completely abolished the integrin 
response to BCR triggering (Fig. 3 C). These data were con-
firmed in ibrutinib-treated CLL cells (n = 7), where the addi-
tion of idelalisib to CLL cells collected at day 30 on ibrutinib 
was able to completely antagonize anti-IgM–induced VLA-4 
activation (Fig. 3 D). The key role of both BTK and PI3K in 
the induction of VLA-4 activation was also observed in nor-
mal B cells from healthy donors (Fig. S1 B), where, similarly 
to what we reported in CLL cells, only concomitant inhibi-
tion of both BTK and PI3K was able to abrogate anti-IgM–
induced VLA-4 activation.
cd49d+ cLL displays reduced ibrutinib-induced 
redistribution lymphocytosis
Absolute lymphocyte count (ALC) data were collected be-
fore treatment and at days 30, 60, 90, and 120 on ibrutinib 
from three independent cohorts of patients receiving ibru-
tinib as single agent (one from Italy [n = 37, hereafter IT 
cohort] and two from the United States: National Institutes 
of Health, Bethesda, MD [n = 34, hereafter NIH cohort] and 
Mayo Clinic, Rochester, MN [n = 30, hereafter Mayo co-
hort]; Materials and methods; Table S1). The median base-
line ALCs were 24.7 × 106/ml, 83.6 × 106/ml, and 68.0 
× 106/ml for the IT, NIH, and Mayo cohorts, respectively. 
Despite these differences, similar trends of ALC kinetics, 
peaking at day 30 of ibrutinib treatment, were found in the 
three cohorts (Fig. 4 A).
We then compared ALC kinetics in CD49d− and 
CD49d+ CLL using the percent ALC change to normalize for 
the differences in ALC absolute values. Heterogeneous base-
Figure 3. concomitant inhibition of BtK and PI3K impairs VLA-4 activation. (A) Phospho (p)-BTK MFI in unstimulated and anti-IgM–stimulated CLL 
cells from seven cases pretreated or not with 1 µM ibrutinib. (B) p-AKT MFI in unstimulated and anti-IgM–stimulated CLL cells pretreated or not with 1 µM 
idelalisib. (c) VLA-4 RO in unstimulated and anti-IgM–stimulated CLL cells untreated or treated with 1 µM ibrutinib, 1 µM idelalisib, or a combination of 
both. (d) VLA-4 RO in unstimulated and anti-IgM–stimulated CLL cells (n = 7) collected at day 30 of ibrutinib therapy and treated or not with 1 µM idelalisib 
in vitro. Data are presented as mean ± SEM. Individual symbols represent individual cases. *, P < 0.05; n.s., not significant (Wilcoxon test).
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line levels of ALC were found in the different cohorts irrespec-
tive of CD49d expression (Fig. 4 A) and, as expected (Herman 
et al., 2014b; Farooqui et al., 2015; Thompson et al., 2015a), 
variability in ALC values was observed in both CD49d− and 
CD49d+ CLL cases upon ibrutinib treatment (Fig. 4 B, top). 
This notwithstanding, in all three cohorts analyzed separately 
or merged together, CD49d+ CLL mostly failed to display 
an increase of the median ALC values at the analyzed time 
points, whereas the typical ibrutinib-induced early peak of 
ALC values was observed in CD49d− CLL (Fig. 4 B, bot-
tom). When considering the later time points at days 60, 90, 
and 120, the trend of percent ALC change in the CD49d+ 
CLL group was again similar among the three different co-
horts (Fig. 4 B, bottom).
The different trends in lymphocytosis from pretreat-
ment to day 30 between CD49d− and CD49d+ CLL were 
also observed in a small group of patients (n = 10) of the 
Mayo cohort, entering the clinical trial NCT02048813 
which introduced rituximab after 30 d of ibrutinib (Materials 
and methods; Table S1). As expected, the addition of ritux-
imab at day 30 resulted in a rapid decrease in ALC values 
in CD49d− CLL, which became superimposable to those of 
CD49d+ CLL at later time points (Fig. S2 A).
Given the influence of CD49d expression on ibruti-
nib-induced lymphocytosis, we next evaluated its expres-
sion in PB CLL cells collected at baseline and after 30 d 
of treatment. A decrease of expression of both VLA-4 sub-
units (CD49d/CD29) was observed at day 30 (Herman et 
al., 2015), without reduction of IgM expression (Fig. 5 A). 
Notably, such a decrease occurred also in the context of the 
CXCR4dim/CD5bright population, which has been reported 
to represent the proliferative fraction, highly enriched in 
cells that have just been released from lymphoid tissues, 
where activation and proliferation occur (Fig. 5, B and C; 
Calissano et al., 2011).
cd49d+ cLL displays reduced ibrutinib-induced Ln shrinkage
We then evaluated the impact of CD49d expression on the 
extent of lymphadenopathy reduction induced by ibrutinib 
therapy. Sum of the product of diameter (SPD) values of the 
Figure 4. cd49d+ and cd49d− cLL show different patterns of redistribution lymphocytosis during ibrutinib treatment. ALCs were collected 
pretreatment (day 0) and at different treatment time points (days 30, 60, 90, 120) in CLL cases from three different cohorts. (A) Kinetics of ALC (median 
values) in the IT cohort (left), NIH cohort (middle), and Mayo cohort (right); the gray and red symbols in each graph correspond to the pretreatment median 
ALC in CD49d− and CD49d+ CLL, respectively. (B) Percent ALC change from baseline in CLL cases split according to CD49d expression (CD49d+, red; CD49d−, 
gray) from the three individual cohorts and the merging of all cohorts, shown as individual plots (above graphs) and as median values (below graphs). The 
number of patients included in each group are reported in parentheses; the black vertical lines indicate SEM. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; 
n.s., not significant (Mann–Whitney test).
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major LN regions were available before treatment and at 2, 6, 
or 12 mo on therapy (Table S1). Nodal response was calcu-
lated as percent reduction in SPD values, as reported previ-
ously (Byrd et al., 2013). Overall, the median LN reduction 
was 54.8% at 2 mo (n = 33, NIH cohort), 76.2% at 6 mo (n 
= 33, NIH cohort), and 86.1% at 12 mo (n = 53, NIH and IT 
cohorts; Fig. S2 B). We observed a trend toward lower median 
LN reduction in CD49d+ CLL compared with CD49d− CLL 
at 2 mo (CD49d+ CLL, n = 20; CD49d− CLL, n = 13; Fig. 
S2 C, top), which manifested in a significant effect at both 
6 mo (CD49d+ CLL, n = 20; CD49d− CLL, n = 13; Fig. 
S2 C, bottom) and 12 mo (CD49d+ CLL, n = 30; CD49d− 
CLL, n = 23; Fig. 6, A and B). On the contrary, the degree 
of nodal response was not correlated with other prognostic 
markers, including TP53 disruption, defined by the presence 
of either TP53 mutation or 17p−, and IGHV mutational 
status (Fig. 6, C and D).
Correlation analyses between the levels of CD49d ex-
pression, defined as percentage of positive cells (all cohorts) 
or mean fluorescence intensity (MFI) values (IT cohort), and 
the ibrutinib-induced responses (i.e., ALC change at day 30 
and percent SPD change at 12 mo), where the largest number 
of cases were available, highlighted a significant relationship 
that was mainly driven by the negative/positive expression of 
CD49d (i.e., below or above the 30% cutoff; Fig. S3, A–C). 
This observation is in line with the functional data on VLA-4 
activation, where the 30% CD49d expression value roughly 
corresponded to the threshold amount of VLA-4 molecules 
that has to be present on the cell surface to detect an effective 
inside-out activation by BCR triggering (see above; Fig. 1 F).
cd49d expression is correlated with 
shorter PFs under ibrutinib
At the median follow up of 24.5 mo, 28 (27.7%) of 101 pa-
tients progressed or died on study.
An univariate analysis was performed testing the prog-
nostic relevance as PFS predictors of CD49d expression 
(CD49d+, n = 55) and other biological and clinical bio-
markers (Table S1), including age (>65 yr, n = 54), gen-
der (males, n = 60), Rai stage (III–IV Rai stage, n = 55), 
treatment-naive (TN)/refractory-relapsed (RR) status (RR 
cases, n = 69), white blood cell count, β2 microglobulin (≥ 
4 mg/l, n = 37), IGHV gene mutational status (UM IGHV, 
n = 67), TP53 disruption (TP53 disrupted, n = 42), and 11q 
deletion (del11q, n = 19).
Significantly inferior PFS was observed with CD49d+ 
CLL compared with CD49d− CLL (Fig. 7 A and Table 1), 
whereas among the other variables, only TP53 disruption, 
IGHV gene mutations, and the TN/RR status predicted 
shorter PFS, in keeping with previously reported observa-
tions (Byrd et al., 2015; Ahn et al., 2017; Fig.  7, B–D; and 
Table  1). The lack of impact of the other baseline charac-
teristics on PFS is consistent to what was observed in the 
ibrutinib arm of the stage 3 RES ONA TE study or other 
studies of real-world experience with ibrutinib (Winqvist et 
al., 2016; Brown et al., 2017).
Of note, the concomitant presence of CD49d+ expres-
sion and TP53 disruption (Fig. 7 E) or UM IGHV (Fig. 7 F) 
predicted significantly inferior PFS compared with the pres-
ence of either factor alone.
When testing a multivariate Cox regression analysis, 
four variables were considered: CD49d expression, TP53 sta-
tus, IGHV gene status, and the TN/RR status. In our con-
text, because of the low number of events, a multivariate 
analysis with more than three variables was not statistically 
recommended (Peduzzi et al., 1995). Therefore, a panel of 
multivariate analyses, which included all of the three-variable 
combinations of CD49d with the other main predictors, was 
performed. As summarized in Table 1, the results suggest that 
the three biological variables (i.e., CD49d, TP53 disruption, 
and IGHV gene status) emerged as independent predictors in 
models including TN/RR status. Consistently, high CD49d 
expression, the presence of TP53 disruption, and UM IGHV 
gene status (which did not reach statistical significance) iden-
tified a patient subset with shorter PFS intervals in the con-
text of the RR cohort (Fig. 7, G–I).
dIscussIon
The interaction between VLA-4 and the BCR has been 
described in B lymphocytes, where it contributes to anti-
gen-specific B cell differentiation (Spaargaren et al., 2003; 
Figure 5. VLA-4 expression decreases after ibrutinib therapy. (A) 
Flow-cytometric determination of CD49d, CD29, and IgM MFI in CLL cells 
collected at days 0 and 30 on ibrutinib. (B) Representative flow cytom-
etry dot plot showing CXCR4 versus CD5 expression in gated CLL cells. 
The red gate identifies CXCR4dim/CD5bright population. (c) CD49d MFI in the 
CXCR4dim/CD5bright population of CLL cells collected at days 0 and 30 on 
ibrutinib. Data are presented as mean ± SEM. Individual symbols represent 
individual cases. *, P < 0.05; **, P < 0.01; n.s., not significant (Wilcoxon test).
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Arana et al., 2008a). Thus far, this potential interplay has 
not been investigated in the context of CLL. Using a con-
formationally sensitive anti-CD29 antibody and a small 
LDV-containing probe mimicking the VLA-4 ligands, we 
report that signaling through the BCR was sufficient to in-
duce VLA-4 conformation changes resulting in enhanced 
affinity of the integrin (Chigaev et al., 2009). Moreover, 
BCR-induced inside-out signaling also resulted in increased 
clustering of VLA-4 molecules causing higher avidity, as pre-
viously reported in a model of nonhuman B cells (Spaar-
garen et al., 2003). This increased VLA-4 activity was reflected 
by the higher adhesion of the cells to VCAM-1 under static 
and shear-flow conditions.
A functional interplay between the BCR and VLA-4 
in the CLL setting has been recently hypothesized follow-
ing observations of inhibitory effects exerted by ibrutinib on 
VLA-4–mediated CLL cell adhesion (de Rooij et al., 2012; 
Herman et al., 2015). Here, by taking advantage of both in 
vitro and in vivo ibrutinib-treated CLL cells, we could con-
firm the relationship between ibrutinib exposure and im-
paired CLL cell adhesion on VCAM-1 substrates (which was 
more apparent in cells derived from in vivo treatment), with 
increased inhibition after 30 d of therapy. Consistently, during 
in-vivo ibrutinib treatment, we described a progressive re-
duction of constitutive VLA-4 activation that was paralleled 
by a diminished constitutive phosphorylation of BCR-related 
Figure 6. cd49d+ and cd49d− cLL are characterized by different ibrutinib-induced nodal responses. LN dimension evaluation was performed 
pretreatment and at 12 mo of ibrutinib therapy, and the sum of the products of LN diameters (SPD) of up to five LN regions was calculated. (A) Waterfall 
plot showing the percent SPD change from baseline in CD49d+ (red bars) or CD49d− (gray bars) CLL cases. (B–d) The box and whisker plot shows the median 
percent SPD change in CLL cases split according to CD49d expression (CD49d−, n = 23; gray box; CD49d+, n = 30; red box; B), TP53 disruption (no TP53 
disruption, n = 24; blue box; TP53 disruption, n = 28; orange box; C), and IGHV mutations (UM, IGHV, n = 35; blue box; mutated [M] IGHV, n = 18; orange 
box; D). *, P < 0.05; n.s., not significant (Mann–Whitney test).
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Figure 7. PFs of ibrutinib-treated cLL patients. (A-I) Kaplan–Meier estimates of PFS of CLL patients treated with ibrutinib and stratified by CD49d 
expression (A), TP53 disruption (B), IGHV mutational status (C), prior treatment (D), the association of CD49d expression and TP53 disruption (E), the asso-
ciation of CD49d expression and IGHV mutational status (F), CD49d expression in the context of RR CLL (G), TP53 disruption in the context of RR CLL (H), 
and IGHV mutational status in the context of RR CLL (I). The number of patients included in each group are reported in parentheses. *, P < 0.05; **, P < 0.01; 
n.s., not significant (log-rank test).
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proteins. This inhibition of BCR signaling occurring in the 
absence of BCR cross-linking, which was previously ob-
served (Herman et al., 2014a; Woyach et al., 2014b), suggests 
that BTK inhibition by ibrutinib by abrogation of anti-
gen-independent cell-autonomous signaling (Dühren-von 
Minden et al., 2012) may also affect the constitutive VLA-4 
activation state via inside-out mechanisms.
Unexpectedly, when triggering the BCR in CLL cells 
treated with ibrutinib either in vitro or in vivo, VLA-4 was still 
capable of being inside-out activated, as clearly determined 
by both a conformation change consistent with an increased 
affinity (Chigaev et al., 2009) and an increased capability to 
form clusters (Spaargaren et al., 2003). In keeping with the 
maintenance of this double functionality of the integrin ac-
tivation process, VLA-4–expressing CLL cells retained the 
capability to bind VLA-4 substrates upon BCR engagement, 
even in the presence of ibrutinib. Although the present study 
represents the first to investigate the VLA-4 activation state in 
CLL, adhesion assays of CLL cells in the presence or absence 
of ibrutinib have been reported earlier (de Rooij et al., 2012; 
Herman et al., 2015). These studies, however, either did not 
address cellular adhesion upon BCR triggering (Herman et 
al., 2015) or lacked information about the VLA-4 (CD49d) 
expression state of CLL cases used for these adhesion assays 
(de Rooij et al., 2012).
The observation that BCR engagement was still able 
to induce VLA-4 activation and VLA-4-mediated adhesion in 
ibrutinib-treated CLL cells, as shown here, could have been 
caused by a total or partial lack of BTK inhibition in CLL 
cells. However, the following findings argue against this pos-
sibility: (a) the addition of an excess of ibrutinib in vitro to 
CLL cells derived from patients treated for 30 d with ibru-
tinib did not further inhibit the constitutive and anti-IgM–
stimulated phosphorylation status of BTK and had no impact 
on the constitutive or anti-IgM–stimulated VLA-4 activation 
level; and (b) samples used in our experiments had functional 
BTK and showed no evidence of specific BTK or PLCγ2 
mutations, whose emergence has been described to confer 
resistance to ibrutinib (Woyach et al., 2014a; Liu et al., 2015; 
Ahn et al., 2017).
In our hands, ibrutinib effectively inhibited BCR sig-
naling in terms of calcium release, BTK phosphorylation, and 
phosphorylation of PLCγ2, the immediate downstream target 
of BTK (Spaargaren et al., 2003), but exhibited partial inhibi-
tion of p-AKT and no inhibition of p-ERK (Rickert, 2013). 
A controversial impairment of AKT and ERK activation by 
BCR triggering in CLL cells of patients treated with ibrutinib 
for 9 mo has been reported (Woyach et al., 2014b) and was al-
legedly caused by anergic features of these samples, manifest-
ing in a lack of responsiveness to BCR stimulation also at the 
pretreatment stage in many instances (Apollonio et al., 2013).
The precise signaling cascade underlying BCR-induced 
VLA-4 activation is far from being understood. The current 
knowledge derives from studies of normal B cell differen-
tiation, where membrane-bound antigens, e.g., on the sur-
face of follicular dendritic cells, can be presented via BCR to 
germinal center B cells, with subsequent inside-out VLA-4 
activation that can facilitate the survival through VLA-4/
VCAM-1 interactions, especially for those B cells express-
ing an appropriate BCR (Carrasco and Batista, 2006). In 
this context, BCR triggering can activate VLA-4 through an 
axis involving BTK, and eventually regulating VLA-4 avid-
ity (Spaargaren et al., 2003). A parallel axis, involving PI3K 
and bypassing BTK has been reported (Arana et al., 2008b), 
although most of the knowledge on PI3K involvement in 
inside-out integrin activation mechanisms stems from studies 
on LFA-1 rather than VLA-4 integrin.
The maintenance of a certain degree of phosphoryla-
tion of AKT, a protein located downstream PI3K in the BCR 
signaling cascade, may suggest residual anti-IgM–induced 
BCR signaling activity that in turn may be responsible for the 
observed BCR-related VLA-4 activation that occurs during 
ibrutinib treatment. Indeed, addition of the PI3K inhibitor 
idelalisib to both in vitro and in vivo ibrutinib-treated CLL 
cells completely abolished anti-IgM–induced VLA-4 activa-
tion. Consistently, the concomitant inhibition of BTK and 
PI3K by ibrutinib and idelalisib, respectively, has been shown 
to hamper BCR-stimulated integrin-mediated CLL cell ad-
hesion in a strong synergistic manner (de Rooij et al., 2015).
VLA-4 is also expressed at high levels in PB normal B 
cells of healthy donors (Möller et al., 1992). Moreover, we 
provide evidence that BCR stimulation can inside-out acti-
Table 1. univariate and multivariate cox regression analysis of PFs 
in ibrutinib-treated cLL
Analysis HR (95% CI) P
univariate analysis
 Age ≥65 yr 0.48 (0.22–1.05) 0.068
 Sex, male 0.50 (0.24–1.06) 0.071
 III–IV Rai stage 1.30 (0.56–3.03) 0.548
 Therapy, RR status 3.14 (1.09–9.01) 0.034
 WBC count 1.00 (1.00–1.00) 0.364
 β2M ≥4 mg/L 1.06 (0.43–2.62) 0.894
 CD49d+ 3.32 (1.35–8.17) 0.009
 UM IGHV 5.48 (1.65–18.17) 0.006
 TP53 disrupted 2.71 (1.14–6.43) 0.025
 Del11q 0.52 (0.16–1.74) 0.291
Multivariate analysis
 Model 1
 CD49d+ 3.15 (1.16–8.53) 0.025
 UM IGHV 4.17 (1.23–14.15) 0.023
 TP53 disrupted 2.83 (1.18–6.82) 0.021
 Model 2
 CD49d+ 2.61 (1.03–6.61) 0.043
 UM IGHV 4.32 (1.26–14.81) 0.020
 Therapy, RR status 1.53 (0.50–4.65) 0.457
 Model 3
 CD49d+ 2.61 (0.95–7.16) 0.065
 TP53 disrupted 3.00 (1.24–7.29) 0.016
 Therapy, RR status 3.71 (0.83–16.59) 0.087
White blood cell count was considered as continuous variable. β2M, β2 microglobulin; 
CI, confidence interval; Del11q, according to Döhner et al. (2000); HR, hazard ratio; RR, 
relapsed-refractory; UM, unmutated; WBC, white blood cell.
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vate VLA-4 also in these cells and that concomitant inhibition 
of BTK and PI3K blocks such activation. This suggests that 
the mechanisms observed in CLL can be considered a rem-
nant of activity occurring in normal B cells (e.g., during the 
antigen-dependent differentiation process occurring in lym-
phoid organs; Carrasco and Batista, 2006).
The variability in degree and kinetics of ibruti-
nib-induced recirculation lymphocytosis, considered a class 
effect of BCR pathway inhibitors, has been highlighted by 
several studies (Herman et al., 2014b; Farooqui et al., 2015; 
Thompson et al., 2015a) and was also confirmed in all three 
patient cohorts investigated in the present study. Despite this 
observation, we here report a different pattern of recircula-
tion lymphocytosis upon ibrutinib treatment by comparing 
the median ALC kinetics of CLL cases expressing or not the 
VLA-4 α chain CD49d. In fact, the typical ibrutinib-induced 
early peak of lymphocytosis was found in CD49d− CLL, but 
not in CD49d+ cases. Notably, such different behavior be-
tween CD49d+ and CD49d− CLL was documented in co-
horts with different mean ALCs before treatment and involved 
patients enrolled in different clinical trials, named patient pro-
grams (NPP), and from the real world, thus implying that the 
observed effects did not occur because of the selection of a 
particular group of patients. Interestingly, the ALC kinetics 
characterizing CD49d+ CLL were similar to those observed 
in previous studies of UM IGHV CLL and trisomy 12 CLL 
(Farooqui et al., 2015; Thompson et al., 2015a). Although data 
on CD49d expression were unavailable in these studies, it is 
known that almost all trisomy 12 CLL cases express CD49d 
and that CD49d+ CLL usually has UM IGHV (Gattei et al., 
2008; Zucchetto et al., 2013; Dal Bo et al., 2016).
Undoubtedly, ibrutinib has exceptional activity in pa-
tients with RR CLL, as well as in untreated patients with 
genetic abnormalities that predict chemoresistance (i.e., TP53 
deletion or mutation), where a significant reduction in or-
ganomegaly and LN size is observed in most cases (Byrd et 
al., 2014). In the present study, analysis of nodal response in 
patients from a phase II clinical trial and an NPP confirmed 
the remarkable ibrutinib-mediated reduction of lymphade-
nopathies. Nevertheless, when comparing the extent of nodal 
response in CD49d− and CD49d+ CLL, a trend of lower re-
sponse was already observable after 2 mo of ibrutinib treat-
ment in CD49d+ CLL, a difference that became significant 
after 6 and 12 mo. In contrast, no correlation between nodal 
response and other prognostic parameters, including TP53 
disruption and IGHV mutational status, was observed. An 
overall sustained nodal response also in cases without an ap-
parent ALC change, as observed in CD49d+ CLL, can be 
explained by the gradual release of cells from nodal compart-
ment because of the presence of a still-active VLA-4 integrin 
on the CLL cell surface. On the contrary, CD49d− CLL cells, 
lacking one of the key molecules involved in cell adhesion, 
can be rapidly released into blood circulation, yielding the ex-
pected peak of redistribution lymphocytosis. Another possible 
mechanism explaining the lack of ALC rise in CD49d+ CLL 
relies upon the notion that CD49d+ CLL cells, being more 
addicted to microenvironmental-driven survival mechanisms, 
may more rapidly undergo cell death when released into the 
PB than CD49d− CLL cells (Burger et al., 2017). A simi-
lar mechanism has been postulated to explain the prominent 
redistribution lymphocytosis observed in some instances in 
CLL patients with M IGHV (Woyach et al., 2014b).
Another observation of the present study is that the in-
verse relationship between ALC/SPD changes and CD49d 
expression values was mainly driven by negative/positive 
CD49d expression, thus emphasizing the relevance of the 
clinical cutoff established to identify CD49d+ CLL (Bulian 
et al., 2014). Similarly, evidence was provided that CD49d 
expression levels above the clinical cutoff, were necessary to 
effectively allow BCR-induced inside-out VLA-4 activation. 
In keeping with this line of reasoning, it has recently been 
shown that CLL cases expressing CD49d above the 30% of 
positive cells cutoff are characterized by a more frequent 
nodal presentation and subsequent development of lymph-
adenopathy (Strati et al., 2017).
Since the introduction of ibrutinib for CLL treatment, 
despite the durable clinical responses in the majority of pa-
tients, events of progression have started to be described, 
mainly because of the acquisition of BTK or PLCγ2 muta-
tions (Woyach et al., 2014a; Liu et al., 2015; Ahn et al., 2017). 
Here, we report that patient outcome after ibrutinib treat-
ment can be affected by the presence of the VLA-4 integ-
rin on the surface of CLL cells. Indeed, CD49d+ CLL were 
characterized by inferior PFS than CD49d− CLL. More-
over, the concomitant presence of TP53 disruption and high 
CD49d expression selected a patient subset at higher risk 
of progression, even if compared with cases with TP53 dis-
ruption but lacking CD49d expression. In this regard, it is 
tempting to speculate that CLL cells with the concomitant 
presence of VLA-4, which is responsible for the retention of 
CLL cells in tissue sites, and TP53 disruption, in turn re-
sponsible for genetic instability, may be particularly prone to 
develop ibrutinib resistance.
Collectively, the data presented in this study suggest that 
VLA-4–expressing CLL cells residing in the secondary lym-
phoid organs can receive BCR-mediated stimuli that are able 
to induce inside-out VLA-4 activation even in the presence 
of BTK blockade by ibrutinib. This activation leads to en-
hanced retention of VLA-4+ CLL cells in tissue sites with a 
parallel reduction of redistribution lymphocytosis and a rela-
tively lower and/or slower nodal response eventually affecting 
patient outcome. It is tempting to speculate that the relative 
reduction of CD49d expression observed in PB CLL cells 
from ibrutinib-treated CD49d+ CLL cases, also documented 
in the context of the early released CLL cell subpopulations 
expressing the CXCR4dim/CD5bright phenotype (Calissano et 
al., 2011), could be caused by the release from tissue sites 
of the cells with fewer surface CD49d molecules within the 
CLL clone, whereas CLL cells with the highest CD49d ex-
pression within the clone can be more likely retained in tissue 
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sites. A formal proof for this hypothesis could be obtained by 
comparing CD49d expression and activation, before and after 
ibrutinib treatment, in the context of tissue sites.
From a practical standpoint, our data suggest that eval-
uation of CD49d expression in patients initiating ibrutinib 
therapy may identify those cases that would benefit from 
combination therapy approaches designed to completely 
block VLA-4 activation and VLA-4–mediated retention of 
leukemic cells in protective tissue compartments (de Rooij 
et al., 2015, 2016). Larger CLL cohorts or a more compre-
hensive characterization of CLL cases, which includes the 
novel genetic lesions or the detection of complex karyo-
type (Thompson et al., 2015b; Dal Bo et al., 2016), are 
needed to definitely validate CD49d as progression predictor 
in ibrutinib-treated CLL.
MAtErIALs And MEtHods
cLL patients
This study included CLL patients treated with ibrutinib in 
the context of NPPs, clinical trials, or the real world, as fol-
lows: (1) 37 refractory/relapsed CLL patients enrolled in a 
multicenter Italian NPP and referred to the Clinical and Ex-
perimental Onco-Hematology Unit of the Aviano National 
Cancer Institute as reference laboratory (IT cohort); (2) 34 
out of 86 CLL patients enrolled in the phase II monocentric 
trial NCT01500733 (NIH cohort). Patients from this cohort 
were chosen for the availability of CD49d expression data; no 
differences in terms of the patient’s characteristics (Table S2) 
were found between these patients and the remaining cases 
(Herman et al., 2014b); (3) 40 CLL patients, representing a 
consecutive cohort of patients enrolled by a single institution 
(Mayo Clinic, Rochester, MN) in the phase II multicenter 
trial NCT01744691 or in the phase III US-wide multicenter 
trials NCT01578707, NCT01886872, and NCT02048813 or 
treated with ibrutinib in the real-world (Mayo cohort); (4) 8 
CD49d+ CLL patients from the phase II trial NCT02007044 
provided by the MD Anderson Cancer Center (MDA cohort) 
solely used for in vitro experiments. Patients were treated with 
ibrutinib at a dose of 420 mg daily as a single agent, with the 
only exception of those enrolled in clinical trial NCT02048813 
who also received rituximab starting from day 30.
In vitro studies were performed on PB mononuclear 
cells (PBMCs) and purified CLL cells from CD49d+ CLL of 
the IT and MDA cohorts collected pretreatment, and after 
days 7, 30, or 90 on ibrutinib, and from CD49d+ ibrutinib- 
naive CLL patients by taking advantage of the Aviano (Italy) 
and Salzburg (Austria) CLL biobanks.
Table S1 summarizes the main clinical and biological 
parameters, including CD49d expression, IGHV mutational 
status, and the main cytogenetic abnormalities of CLL cases 
entering this study. A CLL case was considered CD49d+ or 
IGHV mutated according to the 30% or 2% cutoffs, respec-
tively, and cytogenetic categories were defined according 
to Döhner classification (Döhner et al., 2000; Gattei et al., 
2008; Bulian et al., 2014).
All patient samples were collected after informed consent 
in accordance with the declaration of Helsinki and under 
approval of the specific local ethics committee (approval IRB-
05-2010 and IRB-05-2015 of the Centro di Riferimento 
Oncologico, Aviano, and approvals 415-E/1287/4-2011 and 
415-E/1287/13-2016 of the Salzburg ethics committee). All 
trials were registered at www .clinicaltrials .gov.
PBMc isolation and cLL cell purification
PBMCs were isolated by density-gradient centrifugation (Fi-
coll Lymphocyte Separation Media, GE Healthcare), cryo-
preserved in 90% FBS (Sigma-Aldrich) plus 10% dimethyl 
sulfoxide (Sigma-Aldrich), and stored in liquid nitrogen until 
use. When reported, in vitro treatments were performed with 
1 µM ibrutinib (Axon Medchem BV) for 1 h at 37°C and 
with 5 µg/ml F(ab)2 anti-IgM (catalog 109.006.129; Jack-
son ImmunoResearch), or 5 µg/ml F(ab)2 anti-IgD (cata-
log 2032–01; Southern Biotechnology) for the indicated 
time periods (Herman et al., 2015; Ten Hacken et al., 2016). 
For specific experiments, CLL cells were purified by nega-
tive selection using a mixture of anti-CD3, anti-CD16, and 
anti-CD14 mAbs (provided by F. Malavasi, University of 
Turin, Turin, Italy) and separation by immunomagnetic beads 
(Thermo Fisher Scientific) or left untouched when the CLL 
cells purity was >95% (Zucchetto et al., 2012). In all cases, B 
cell purity was >95%, as assessed by flow cytometry.
Flow cytometry
For immunophenotypic evaluations, PBMCs from CLL sam-
ples were stained with anti-CD19 PE-Cy7 (catalog 560728; 
BD Biosciences) and anti-CD5 APC or CD5 FITC (catalog 
555355 and 555352; BD Biosciences) mAbs, to identify CLL 
cells, with DAPI (Sigma-Aldrich) to exclude dead cells, and 
with anti-CD49d PE (catalog 555503; BD Biosciences), an-
ti-CD29 PE (catalog 555443; BD Biosciences), anti-CXCR4 
APC (catalog 555976; BD Biosciences), or anti-IgM FITC 
mAbs (catalog F0058; Dako). PBMCs from healthy do-
nors were stained with anti-CD19 BV421 (catalog 562440; 
BD Biosciences), anti-CD49d PE, anti-CD29 PE, anti-IgG 
BB515 (catalog 564581; BD Biosciences), anti-IgM APC 
(catalog 551062; BD Biosciences). For phosphoprotein ex-
pression analysis, PBMCs (5 × 105 per experimental condi-
tion), treated or not with 1 µM ibrutinib (1 h at 37°C) and 
stimulated for 10 min with either 5 µg/ml F(ab)2 anti-IgM 
or F(ab)2 isotypic control (catalog LS-C351727; LSBio), were 
stained with anti-CD3 BV605 (catalog 563219; BD Biosci-
ences) and anti-CD19 BV421 mAbs and then fixed with Fix 
Buffer I (BD Biosciences) and permeabilized with 90% ice-
cold methanol (VWR). Cells were labeled with one of the 
following mAbs: p-ERK (pT202/pY204) Alexa Fluor 488 
(catalog 612592), p-BTK (pY223)/ITK (pY180)-PE (cat-
alog 562753), p-PLCγ2 (pY759)-PE (catalog 558490), and 
p-AKT (pS473) Alexa Fluor 488 (catalog 560404) or Alexa 
Fluor 647 (catalog 560343; all from BD Biosciences). In all 
cases, setup experiments with appropriate isotype controls 
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(catalogs 556650 and 557702) were performed to verify 
staining specificity. Cells were analyzed on a FACS Fortessa 
flow cytometer using FACS DIVA software (BD Biosciences) 
upon instrument calibration with CS&T beads (BD Biosci-
ences). The specific fluorescence signals were recorded as ab-
solute MFI values in log10 mode.
calcium assay
PBMCs (5 × 105 per experimental condition) treated or not 
with 1 µM ibrutinib were incubated in RPMI medium (Sigma- 
Aldrich) and 1% FBS with 3 µM Fluo-4 AM (Thermo Fisher 
Scientific) for 30 min at 37°C. Cells were then washed, re-
suspended in RPMI with 1% FBS at 5 × 106 cells/ml, and 
acquired at 37°C on FAC SAria III (BD Biosciences). After a 
baseline acquisition for 1 min, cells were stimulated with 5 
µg/ml F(ab)2 anti-IgM and recorded for another 3 min. To 
calculate the percentage of cells that exhibited increased fluo-
rescence after addition of anti-IgM (percentage of responding 
cells), a background fluorescence threshold (T) at the fluo-
rescence intensity of the 85th percentile of unstimulated cells 
was established for each sample, and the peak percentage of 
cells that exhibited an increase in fluorescence intensity above 
T after treatment with anti-IgM was then calculated (Mock-
ridge et al., 2007). Data were analyzed by FlowJo software 
(Version 10; Tree Star).
tP53, BtK, and PLcγ2 mutational status
TP53 mutational status was performed by a Sanger sequenc-
ing (exons 4–9; Rossi et al., 2013) or by NGS (exons 2–11) 
approaches. BTK C481S mutation and PLCγ2 R665W, 
S707Y and L845F mutations were assessed by NGS. NGS 
analyses were run in a MiSeq sequencer (Illumina) using an 
amplicon-based strategy with at least 1,000× coverage and 
1% of sensitivity. Primer sequences are available upon request. 
Data were analyzed with MiSeq reporter (Illumina) and 
IGV software (Thorvaldsdóttir et al., 2013) against human 
genome assembly hg19.
VLA-4 activation assay
PBMCs (2 × 105 per experimental condition) were incu-
bated with a range of concentrations of the VLA-4–specific 
ligand, LDV-containing probe ((N'-2-methylphenyl ureido)- 
phenyl cetyl-l-leucyl-l-aspartyl-l-valyl-l-prolyl-l-alanyl-l- 
alanyl-l-lysine, LDV; Commonwealth Biotechnologies) in 
the presence of an excess of anti-CD29 PE clone HUTS-
21 mAb (catalog 556049; BD Biosciences), which specifically 
recognizes only the LDV-occupied VLA-4 conformation, for 
30 min at 37°C, as described previously (Chigaev et al., 2009). 
A mixture of anti-CD3 FITC (catalog 555332; BD Biosci-
ences) and anti-CD19 APC (catalog 555415; BD Biosciences) 
mAbs and DAPI were added during the last fifteen minutes 
incubation. Subsequently, the mean fluorescence intensity 
(MFI) of labeled HUTS-21 mAbs was measured, and VLA-4 
RO was determined (ranging from 0.0 [no RO] to 1.0 [100% 
RO]). The criteria used to calculate the EC50 value and the 
resulting VLA-4-RO was the presence of increased HUTS-
21 binding with increased LDV concentration. Under these 
conditions the EC50 of the HUTS-21–binding curve pro-
vides a measure of the VLA-4 ligand-binding affinity. RO was 
also used as an indicator of binding affinity (at 10 nM LDV), 
where higher RO indicates larger fraction of high-affinity 
receptors (Chigaev et al., 2009). When indicated, cells were 
treated with 5 µg/ml F(ab)2 anti-IgM during the above-re-
ported 30-min incubation and/or ibrutinib (1 µM, 1 h pre-
treatment), as described previously (Herman et al., 2015).
VLA-4 clustering assay
Falcon culture slides were coated with 7.5 µg/ml VCAM-1 
(R&D Systems) overnight, washed, and blocked with 2% 
human serum albumin (Merck Millipore). Purified CLL cells 
were incubated for 1 h with or without 1 µM ibrutinib, added 
to the slides, and allowed to adhere for 30 min at 37°C in 
the presence or not of 5 µg/ml F(ab)2 anti-IgM before fixa-
tion with 4% paraformaldehyde. Slides were stained with pri-
mary anti-CD49d antibody (clone AHP1225; Bio-Rad) and 
Cy3-conjugated secondary anti–rabbit antibody. Images were 
taken with an Olympus IX81 microscope. For quantification, 
high-resolution images for cluster analysis were acquired on a 
Leica TCS SP5 II laser scanning microscope using a 63×/1.4-
NA oil-immersion objective (Leica), and the number of clus-
ters was analyzed using ImageJ software.
static adhesion assay
Negatively selected CLL cells treated or not with ibruti-
nib were labeled with the vital fluorochrome calcein AM 
(Thermo Fisher Scientific), seeded (2 × 105 per experimental 
condition) in triplicate onto 96-well flat-bottom VCAM-1–
coated plates (10 µg/ml; R&D Systems), and left to adhere 
for 30 min at 37°C. BSA-coated wells and polylysine-coated 
wells were used as negative and positive control of adhesion, 
respectively. The specificity of cell adhesion was checked by 
using anti-CD49d (clone P1H4) or anti-CD29 (clone 4B4) 
blocking mAbs (provided by A. Colombatti, CRO Aviano 
National Cancer Institute, Aviano, Italy), as previously re-
ported (Zucchetto et al., 2016). Where indicated, 5 µg/ml 
F(ab)2 anti-IgM was added during this incubation period. 
Nonadhered cells were removed by washing with PBS and 
1  mM Ca2+/Mg2+. The relative number of cells bound to 
the substrate was estimated by fluorescence detection in a 
computer-interfaced GeniusPlus microplate reader (Tecan). 
Results are reported as ratio of the mean of adherent cells 
on VCAM-1 over BSA ± SEM.
shear flow assay
Six-channel μ-slides (Ibidi) were coated with VCAM-1 
(R&D Systems) at 4°C overnight, washed, and blocked with 
2% human serum albumin. Purified CLL cells were incubated 
with or without 1 µM ibrutinib and 5 µg/ml F(ab)2 anti-IgM. 
The cells were perfused at 0.5 dyn/cm2 for 1 min at 37°C 
over the coated substrate. The perfusion period was recorded 
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and digitalized. Analysis of the video-recorded segments was 
done using customized image analysis software (Wimasis). Ar-
resting cells were defined as cells remaining stationary for at 
least 3 s on the substrate as previously described (Hartmann 
et al., 2009; Ganghammer et al., 2015).
clinical assessments
ALC data from the IT, NIH, and Mayo cohorts were col-
lected before treatment and after 30, 60, 90, and 120 d on 
ibrutinib. The SPD of up to five LN regions (laterocervical, 
axillary, mediastinal, abdominal, and inguinal) was computed 
at 2 mo (NIH cohort), 6 mo (NIH cohort), and 12 mo (NIH 
and IT cohorts) on ibrutinib from computer tomography 
scan or physical examination. Patients undergoing progres-
sion and/or Richter syndrome transformation within 12 mo 
were excluded from SPD evaluation.
For clinical evaluations, PFS was defined as the time 
from the start of ibrutinib until progression or death (Cheson 
et al., 1999). Treatment response was evaluated according to 
2008 revised International Workshop on CLL (IWC LL), in-
corporating the 2012 clarifications for patients treated with 
kinase inhibitors as previously reported (Hallek et al., 2008; 
Farooqui et al., 2015; Ahn et al., 2017). OS was defined as 
the time from the start of ibrutinib until last follow-up or 
death. Probability of PFS was estimated by the Kaplan–Meier 
method, and patients alive and progression-free were cen-
sored at the last follow-up. The log-rank test was used to 
compare PFS probabilities between subgroups. Median fol-
low-up was computed using the OS database and by apply-
ing the inverted censoring method. Cox proportional hazards 
regression models were used to assess the independent ef-
fect of variables on PFS.
statistics
All statistical analyses were performed using MedCalc soft-
ware (Mariakerke) and GraphPad Prism 5. All data were tested 
for normal distribution. Normally distributed data were com-
pared using t tests (paired or unpaired), and nonparametric 
data were compared using the Mann–Whitney test (indepen-
dent) or Wilcoxon high-rank test (paired analysis). Categor-
ical data were compared with Fisher’s exact test. For all tests, 
significance levels were defined as *, P < 0.05; **, P < 0.01; 
***, P < 0.001; and ****, P < 0.0001.
online supplemental material
Fig. S1 shows data on the effects of BCR triggering and of 
ibrutinib treatment in both normal B cells and CLL cells. 
Fig. S2 shows data of lymphocytosis in CD49d+ and CD49d− 
CLL from the NCT02048813 clinical trial and the ibruti-
nib-induced nodal response in all CLL after 2, 6, and 12 mo 
of therapy and in CD49d+ and CD49d− CLL after 2 mo and 
6 mo of therapy. Fig. S3 shows correlation analyses between 
the levels of CD49d expression and ibrutinib-induced clinical 
effects. Table S1 lists the clinical and biological information of 
all CLL cases used in this study. Table S2 shows comparisons 
between the clinical and biological features of patients used in 
this study and those of the remaining patients from the phase 
II monocentric trial NCT01500733 (NIH cohort).
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